Clinical Trial Detail

NCT ID NCT04284228
Title Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors NexImmune Inc.
Indications

myelodysplastic syndrome

acute myeloid leukemia

Therapies

Cyclophosphamide + Fludarabine + NEXI-001 T Cells

Age Groups: adult senior

No variant requirements are available.